Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Releases Earnings Results, Misses Expectations By $0.01 EPS

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) issued its quarterly earnings results on Tuesday. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. The company had revenue of $1.73 million for the quarter, compared to the consensus estimate of $3.60 million. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Management said OpRegen remains on track in a partner-run open-label GA study, citing expanded site activations and Roche/Genentech language describing the program as potentially disease-modifying. They also highlighted long-term data showing vision gains persisted for at least three years after a single dose in the target location.
• The company emphasized major progress at its AlloSCOPE manufacturing platform, which now supports multiple new programs and could enable low-cost, scalable cell production. Management said this platform is a key differentiator because it focuses on reproducible manufacturing before clinical testing.
• COR1, Lineage’s wholly owned corneal endothelial cell program, advanced into preclinical development after the team successfully manufactured off-the-shelf cells meeting internal identity, morphology, and function criteria. Management plans to move the program into translational studies and then initial human testing.
• The ILT1 diabetes initiative is progressing through scale-up work for undifferentiated pluripotent cells, with management reporting the first internal manufacturing milestone was met. The company stressed that the main risk is proving large-scale manufacturing and differentiation can work reliably, and that this remains a stepwise go/no-go process.
• ReSonance reached an important manufacturing milestone with three successful engineering runs and a new deafening model to support functional testing. Lineage also said its Demant partnership is progressing well and that it expects to move toward GMP material and eventual FDA discussions for human testing.
• Financially, Lineage ended the quarter with $53.4 million in cash, which it says funds operations into Q2 2028. First-quarter revenue rose to $1.7 million, while operating expenses increased to $9.3 million, contributing to a net loss of $4.8 million.

Lineage Cell Therapeutics Trading Down 4.9%

Shares of NYSEAMERICAN LCTX opened at $1.27 on Wednesday. Lineage Cell Therapeutics has a 12-month low of $0.45 and a 12-month high of $2.09. The company has a market cap of $315.36 million, a PE ratio of -4.78 and a beta of 1.60. The stock has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $1.67.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds have recently added to or reduced their stakes in LCTX. DLD Asset Management LP bought a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth $33,000. Kestra Advisory Services LLC lifted its holdings in Lineage Cell Therapeutics by 174.7% in the fourth quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock worth $46,000 after purchasing an additional 17,647 shares during the period. Equitable Holdings Inc. bought a new position in Lineage Cell Therapeutics in the 3rd quarter valued at about $51,000. Jump Financial LLC acquired a new position in Lineage Cell Therapeutics during the 2nd quarter valued at about $28,000. Finally, Jain Global LLC raised its position in shares of Lineage Cell Therapeutics by 202.3% during the 4th quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after buying an additional 26,000 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. D. Boral Capital restated a “buy” rating and set a $3.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, May 4th. Canaccord Genuity Group began coverage on Lineage Cell Therapeutics in a research report on Tuesday, April 28th. They issued a “buy” rating and a $9.00 target price on the stock. B. Riley Financial boosted their price target on shares of Lineage Cell Therapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 24th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $6.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.